Latest News & Features
Asia
The Health Ministry in India has recommended that a compulsory licence is issued for the manufacture of Bristol-Myers Squibb’s anti-cancer drug Sprycel (dasatinib), potentially opening the door to the sale of cheaper imitations. 12 September 2013
Americas
The annual International Association for the Protection of Intellectual Property conference in Helsinki has been assessing the potential problems for pharmaceutical companies trying to brand their medicinal products. 7 September 2013
Asia-Pacific
Law firm Rouse has teamed up with two organisations to open the BioEconomy Academy, an initiative aimed at boosting IP use and awareness in Thailand. 4 September 2013
Asia
There has been much debate about whether there is a global deterioration of IP, and many commentators
would suggest that India is leading the charge. Andrew Jenner and Ernest Kawka reflect on the experiences of innovative biopharmaceutical companies in India. 31 August 2013
Americas
In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP. 31 August 2013
Big Pharma
A decision from an opposition division of the European Patent Office may have “far-reaching consequences” for US patent holders, Solveig Moré tells LSIPR. 31 August 2013
Americas
The American Civil Liberties Union and other groups have submitted an amici curiae brief in support of Ambry Genetics and Gene by Gene in their patent infringement cases with Myriad Genetics Inc. 30 August 2013
Biotechnology
UK IP firm Marks & Clerk LLP has announced two of its attorneys will be joining the firm’s partnership. 28 August 2013
Big Pharma
Austria has become the first country in the EU to ratify consent to the Unified Patent Court. 27 August 2013
Americas
Eli Lilly has begun its defence of a patent covering lung cancer drug Alimta against generic companies including Teva, Barr Laboratories and APP Pharmaceuticals. 23 August 2013